Pregnancy outcome following prescription for sumatriptan

Headache

Volumn 40, Issue 1, 2000, Pages 20-24

  Olesen, Charlotte ^a   Steffensen, Flemming Hald ^c   Sørensen, Henrik Toft ^b   Nielsen, Gunnar Lauge ^d   Olsen, Jørn ^a  

^a UNIVERSITY OF AARHUS   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d Section of Preventive Medicine   (Denmark)

Author keywords

Low birth weight; Pregnancy; Preterm birth; Sumatriptan

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENMARK; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; LOW BIRTH WEIGHT; MIGRAINE; PREGNANCY; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; FEMALE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; MATERNAL EXPOSURE; MIGRAINE DISORDERS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRESCRIPTIONS, DRUG; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0033980858     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2000.00003.x     Document Type: Article

References (22)

1. Rasmussen BK, Jensen R, Scroll M, Olesen J. Epidemiology of headache in a general population: a prevalence study. J Clin Epidemiol. 1991;44:1147-1157.
2. Massey EW. Migraine during pregnancy. Obstet Gynecol. 1977;32:693-696.
3. Reik L Jr. Headaches in pregnancy. Semin Neurol. 1988;8:187-192.
4. Silberstein SD. Headaches and women: treatment of the pregnant and lactating migraineur. Headache. 1993;33:533-540.
5. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
6. Fullerton T, Gengo FM. Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migaine. Ann Pharmacother. 1992;26: 800-808.
7. Gaist D, Andersen M, Aarup AL, Hallas J, Gram LF. Use of sumatriptan in Denmark 1994-5: epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol. 1997;43:429-433.
8. Hoskins SP. Ergotamine use in pregnancy. Aust N Z J Obstet Gynaecol. 1996;36:159-160.
9. Hughes HE, Goldstein DA. Birth defects following maternal exposure to ergotamine, beta blockers, and caffeine. J Med Genet. 1988;25:396-399.
10. Grauwiler J, Schon H. Teratological experiments with ergotamine in mice, rats, and rabbits. Teratology. 1973;7:227-236.
11. Altman SG, Waltman R, Lubin S, Reynolds SF. Oxytocic and toxic actions of dihydroergotamine. Am J Obstet Gynecol. 1952;64:101-109.
12. Graham JM, Marin PM, Hoefnagel D. Jejunal atresia associated with Cafergotamine ingestion during pregnancy. Clin Pediatr (Phila). 1983;22:226-228.
13. Sirrat GM. Prescribing problems in the second half of pregnancy and during lactation. Obstet Gynecol Surv. 1976:31:1-7.
14. Au KL, Woo JS, Wong VS. Intrauterine death from ergotamine overdosage. Ear J Obstet Gynecol Re-prod Biol. 1985;19:313-315.
15. Raymond GV. Teratogen update: ergot alkaloids? and ergotamine. Teratology. 1995;51:344-347.
16. de-Groot AN, van-Dongen PW, van-Roosmalen J, Eskes TK. Ergotamine induced fetal stress: review of side effects of ergot alkaloids during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1993:51:73-77.
17. Berde B. Pharmacology of ergot alkaloids in clinical use. Med J Aust. 1978;4:3-13.
18. Feniuk W, Humphrey PP, Perren MJ. GR43175 does not share the complex pharmacology of the ergots. Cephalalgia. 1989;(suppl 9):35-39.
19. Nielsen GL, Sørensen HT, Zhou W, Steffensen FH, Olsen J. The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med. 1997; 10:203-205.
20. Wainscott G, Sullivan FM, Volans GN, Wilkinson M. The outcome of pregnancy in women suffering from migraine. Postgrad Med J. 1978;54:98-102.
21. Marcoux S, Berube S, Brisson J, Fabia J. History of migraine and risk of pregnancy-induced hypertension. Epidemiology, 1991;3:53-56.
22. Schuhaiber S, Pastuszak A, Schick B, et al. Pregnancy outcome following first trimester exposure to sumatriptan. Neurology. 1998;51:581-583.